Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Current Deferred Revenue (2021 - 2023)

Historic Current Deferred Revenue for Pulse Biosciences (PLSE) over the last 3 years, with Q1 2023 value amounting to $4000.0.

  • Pulse Biosciences' Current Deferred Revenue fell 7500.0% to $4000.0 in Q1 2023 from the same period last year, while for Mar 2023 it was $4000.0, marking a year-over-year decrease of 7500.0%. This contributed to the annual value of $16000.0 for FY2021, which is N/A changed from last year.
  • As of Q1 2023, Pulse Biosciences' Current Deferred Revenue stood at $4000.0, which was down 7500.0% from $38000.0 recorded in Q3 2022.
  • In the past 5 years, Pulse Biosciences' Current Deferred Revenue ranged from a high of $38000.0 in Q3 2022 and a low of $4000.0 during Q1 2023
  • Moreover, its 3-year median value for Current Deferred Revenue was $16000.0 (2021), whereas its average is $18833.3.
  • In the last 5 years, Pulse Biosciences' Current Deferred Revenue surged by 44285.71% in 2022 and then tumbled by 7500.0% in 2023.
  • Over the past 3 years, Pulse Biosciences' Current Deferred Revenue (Quarter) stood at $16000.0 in 2021, then skyrocketed by 137.5% to $38000.0 in 2022, then crashed by 89.47% to $4000.0 in 2023.
  • Its Current Deferred Revenue was $4000.0 in Q1 2023, compared to $38000.0 in Q3 2022 and $32000.0 in Q2 2022.